The world’s first nasal vaccine from COVID-19 has been officially registered in Russia, RIA Novosti reported. The two-component preparation on the basis of “Satellite V” is introduced by means of a special nozzle – at the moment its use is allowed in medical institutions for patients older than 18 years.
The Ministry of Health of Russia has registered the nasal form of the Gam-Kovid-Vak vaccine (Sputnik V) for the prevention of a new coronavirus infection, developed by the NICEM. Gamalei of the Ministry of Health of Russia “, – it is told in the message of department.
The drug, as well as “Sputnik V”, consists of two components and is injected with a special spray nozzle into the nasal cavity with an interval of three weeks. It forms mucosal immunity to coronavirus infection on the surface of the mucous membrane of the respiratory tract, as well as humoral and cellular immunity in the blood.
“At this stage, the use of the vaccine is allowed in the conditions of medical organizations that carry out vaccine prophylaxis in persons aged 18 and older,” the Ministry of Health explained.
According to the instructions to the drug, contraindications for the use of nasal vaccine are severe allergic reactions, hypersensitivity to the components and acute diseases. Thus, in the exacerbation of chronic diseases, vaccination can be carried out two to four weeks after recovery or remission. In addition, the vaccine should be used with caution in chronic liver and kidney disease, severe hematopoietic disease, epilepsy and other central nervous system diseases, acute coronary syndrome and acute cerebrovascular disorders, myocarditis, endocarditis and pericarditis.
The drug is not contraindicated during pregnancy and breastfeeding, but it should be used from the 22nd week and only in cases where the expected benefit to the mother is higher than the potential risk to the fetus, the instructions say.
According to Interfax, clinical trials of the intranasal form of the Sputnik V vaccine began on January 26. Alexander Ginzburg, director of the Gamalea Center, told the publication that the volunteers did not have any serious side effects after the vaccination. The scientist noted that the vaccine in the form of a spray can be used as additional protection to the main vaccination. In his opinion, the nasal form will be needed first of all for risk groups.
Earlier it became known that the government has allocated 187.8 million rubles. for the first two phases of clinical trials of the intranasal vaccine. And in November 2021, the media reported that Russian President Vladimir Putin received a nasal dose of an experimental drug in powder form.